OVERVIEW OF ACTIVITY

Due to an increased understanding of the biology of renal cell cancer (RCC) and emerging clinical trial data, new therapeutic options are available for patients. To assist medical oncologists, hematologists and hematology-oncology fellows with the formulation of up-to-date management strategies for RCC, this activity features expert perspectives on how the latest research developments apply to current clinical practice.

LEARNING OBJECTIVES

• Apply an understanding of the biology of clear cell RCC, including inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene and the pathway leading to VEGF overexpression, to therapeutic decision-making.
• Develop management strategies for advanced RCC, considering the safety and efficacy profiles of targeted biologic therapies inhibiting VEGF, PDGF and EGF receptors.
• Review clinical efficacy and safety data for inhibitors of the mammalian target of rapamycin (mTOR), and develop a plan for incorporating these agents into treatment plans for advanced RCC.
• Evaluate emerging data on the safety and efficacy of combining targeted therapies for patients with RCC, and apply this information to clinical practice.
• Devise treatment plans for patients with RCC, considering molecular targets and the pathologic grade of the tumor.
• Develop an approach for the sequencing and duration of treatment with targeted biologic therapies.
• Counsel appropriately selected patients with RCC about potential participation in ongoing clinical trials in the adjuvant and metastatic settings.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 3 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains both audio and print components. To receive credit, the participant should listen to the CDs, review the Internet content and complete the Post-test and Educational Assessment located at RenalCellCancerUpdate.com/CME. RenalCellCancerUpdate.com contains edited comments, clinical trial schemas, graphics and references that supplement the audio program, as well as links to relevant full-text articles, abstracts, trial information and other web resources.

This program is supported by educational grants from Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Genentech BioOncology, Pfizer Inc and Wyeth.

Home

Editor
Neil Love, MD

Interviews

Robert A Figlin, MD
- Select publications

Gary R Hudes, MD
- Select publications

Ronald M Bukowski, MD
- Select publications

CME Information

Faculty Disclosures

Editor's Office